Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

Stem-like T cells could improve immunotherapy treatments

Targeting stem-like T cells within certain lymph nodes could improve the number of cancer patients that respond to immunotherapy treatments.

T cells attacking a cancer cell

A team at Yale University, US, have shown that researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters. According to the researchers, targeting these T cells with immunotherapy drugs could increase the number of cancer patients that respond to treatment.

“Therapies that use the immune system to destroy cancer have been a game changer for patients with lung and other cancers,” explained senior author Nikhil Joshi. “But not all people respond to immunotherapy drugs, so it was important for us to discover the role of these special T cells in tumour growth.”

The researchers first developed a new animal model where they could look at the stem-like T cells in tumours over the course of several months of tumour growth and determine how the stem-like T cells survive.

 

access your free copy

 


Biomarkers are redefining how precision therapies are discovered, validated and delivered. 

This exclusive expert-led report reveals how leading teams are using biomarker science to drive faster insights, cleaner data and more targeted treatments – from discovery to diagnostics.

Inside the report:

  • How leading organisations are reshaping strategy with biomarker-led approaches
  • Better tools for real-time decision-making – turning complex data into faster insights
  • Global standardisation and assay sensitivity – what it takes to scale across networks

Discover how biomarker science is addressing the biggest hurdles in drug discovery, translational research and precision medicine – access your free copy today

 

They discovered the stem-like T cells do not persist in the tumour for a long time, suggesting that they are resupplied from somewhere else in the body. Nearby lymph nodes containing many of these stem-like T cells were replenishing the supply. Occasionally, a few stem-like T cells left the lymph node and travel to the tumour, keeping the tumour supplied with fresh cancer fighting T cells. The researchers believe this is important for slowing the growth of cancer. Moreover, an analysis of immune cells isolated from patients with lung cancer confirmed that stem-like T cells are in lymph nodes near the lung.

“T cells in tumours become exhausted, but our study results show the stem-like T cells within the nearby lymph nodes do not experience exhaustion during the course of disease,” said lead author Kelli Connolly. “This could be an important treatment advance as the potential to respond to immunotherapy is preserved.”

“We are focused on developing therapies that will activate the stem-like T cells in the nearby lymph node and bring them into the fight against cancer,” added Joshi. “We plan to continue this work and focus on how to improve these therapeutic responses to help patients.”

The study was published in Science Immunology.